Partial omission of bleomycin for early‐stage Hodgkin lymphoma patients treated with combined modality therapy: Does incomplete ABVD lead to inferior outcomes?

Classical Hodgkin lymphoma (HL) patients achieve excellent outcomes; therefore, treatment de‐escalation strategies to spare toxicity have been prioritized. In a large randomized trial of early‐stage HL patients, omission of chemotherapeutic agents including bleomycin from the standard ABVD (doxorubi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:EJHaem
Autors principals: Gunther, Jillian R., Pinnix, Chelsea C., Glober, Gordon R., Christopherson, Kaitlin M., Fang, Penny, Lee, Hun Ju, Ahmed, Sairah, Steiner, Raphael E., Nair, Ranjit, Strati, Paolo, Neelapu, Sattva S., Nastoupil, Loretta J., Dabaja, Bouthaina S.
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2020
Matèries:
Short Reports
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7455016/
https://ncbi.nlm.nih.gov/pubmed/32864660
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jha2.1
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars